These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38757729)

  • 1. Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration.
    Konstantinidou SK; Argyrakopoulou G; Simati S; Stefanakis K; Kokkinos A; Analitis A; Mantzoros CS
    Diabetes Obes Metab; 2024 Aug; 26(8):3147-3154. PubMed ID: 38757729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study.
    Stefanakis K; Kokkinos A; Argyrakopoulou G; Konstantinidou SK; Simati S; Kouvari M; Kumar A; Kalra B; Kumar M; Bontozoglou N; Kyriakopoulou K; Mantzoros CS
    Diabetes Obes Metab; 2023 Sep; 25(9):2561-2574. PubMed ID: 37246799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2015 Jun; 53(6):19-22. PubMed ID: 26091546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
    Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity.
    Valenzuela-Vallejo L; Chrysafi P; Bello-Ramos J; Bsata S; Mantzoros CS
    Metabolism; 2022 Aug; 133():155237. PubMed ID: 35700837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
    Khalil H; Ellwood L; Lord H; Fernandez R
    Ann Pharmacother; 2020 Jul; 54(7):691-705. PubMed ID: 31958967
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
    Chatzis P; Tziomalos K; Pratilas GC; Makris V; Sotiriadis A; Dinas K
    Folia Med (Plovdiv); 2018 Dec; 60(4):512-520. PubMed ID: 31188761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Tak YJ; Lee SY
    Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naltrexone ER/Bupropion ER: A Review in Obesity Management.
    Greig SL; Keating GM
    Drugs; 2015 Jul; 75(11):1269-80. PubMed ID: 26105116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrave--a combination of bupropion and naltrexone for weight loss.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
    Ali KF; Shukla AP; Aronne LJ
    Expert Rev Clin Pharmacol; 2016; 9(1):27-34. PubMed ID: 26512740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of new antiobesity drugs.
    Hainer V
    Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of New Pharmacological Agents for the Treatment of Obesity.
    Nuffer W; Trujillo JM; Megyeri J
    Ann Pharmacother; 2016 May; 50(5):376-88. PubMed ID: 26887340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A health economic model to assess the cost-effectiveness of OPTIFAST for the treatment of obesity in the United States.
    Nuijten M; Marczewska A; Araujo Torres K; Rasouli B; Perugini M
    J Med Econ; 2018 Sep; 21(9):835-844. PubMed ID: 29678127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
    Grilo CM; Lydecker JA; Morgan PT; Gueorguieva R
    Clin Ther; 2021 Jan; 43(1):112-122.e1. PubMed ID: 33218742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
    Song JE; Ko HJ; Kim AS
    Drug Des Devel Ther; 2024; 18():845-858. PubMed ID: 38524878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
    Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
    Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.